OR WAIT 15 SECS
Ingredients supplier Lonza Group (Basel, Switzerland) has publicly confirmed interest in potentially acquiring capsules manufacturer Capsugel (Greenwood, SC).
Ingredients supplier Lonza Group (Basel, Switzerland) has publicly confirmed interest in potentially acquiring capsules manufacturer Capsugel (Greenwood, SC). According to Lonza’s press announcement today, Capsugel “would fit perfectly with Lonza’s Healthcare Continuum strategy and strengthen its position as a leading supplier to a number of important healthcare markets.” According to The Wall Street Journal, Lonza would purchase Capsugel from private-equity firm KKR for more than $5 billion.
Lonza said it has “expressed a strong interest in this successful company,” but said that at this time it cannot confirm whether an acquisition will be completed.
Focused on two market segments, pharma/biotech and specialty ingredients, Lonza has more than 40 global manufacturing and R&D facilities, approximately 9,800 full-time employees worldwide, and CHF 3.8 billion in sales in 2015. Capsugel performs manufacturing in 13 manufacturing sites across nine countries and has three R&D centers. It produces 200 billion hard capsules and 3 billion finished-dosage units per year for more than 4,000 customers in over 100 countries.
Nutritional Outlook magazine